Matching articles for "chelating agents"
Issue 1347 · September 20, 2010 Free
Nonstandard Uses of Chelation Therapy

Chelation therapy involves oral administration, intravenous infusion or intramuscular injection of drugs that increase excretion of heavy metals. The Medical Letter’s last article on this subject found no…

Med Lett Drugs Ther. 2010 Sep 20; 52(1347):75-6
Chelation therapy involves oral administration, intravenous infusion or intramuscular injection of drugs that increase excretion of heavy metals. The Medical Letter’s last article on this subject found no evidence that it was effective for treatment of cardiovascular disease. Since then, off-label use of chelation therapy has expanded to include treating children with autism and adults with Alzheimer’s disease, cancer and other chronic diseases. Click here to view the free full article.
Issue 1233 · April 24, 2006
Deferasirox (Exjade): A New Iron Chelator

Deferasirox ( Exjade - Novartis), an oral chelating agent, recently received accelerated approval from the FDA as an orphan drug for oral treatment of chronic iron overload due to blood transfusions…

Med Lett Drugs Ther. 2006 Apr 24; 48(1233):35-6
Deferasirox ( Exjade - Novartis), an oral chelating agent, recently received accelerated approval from the FDA as an orphan drug for oral treatment of chronic iron overload due to blood transfusions (transfusional hemosiderosis) in patients >2 years old. Deferasirox is a tridentate (2 molecules of deferasirox bind to one atom of iron) chelating agent with high affinity for iron. It has much lower affinity for zinc and copper.